A case of <scp>COVID</scp>‐19‐associated C‐<scp>ANCA</scp> vasculitis, was successfully treated with rituximab therapy
Both C-anti-neutrophil cytoplasmic antibody (ANCA) and P-ANCA vasculitis were reported to be associated with COVID-19 infection. The ideal management of COVID-19-associated ANCA vasculitis is unclear, as the experiences were limited to case reports. We presented a case of COVID-19-associated C-ANCA vasculitis, successfully treated with steroids and rituximab therapy without any significant adverse reactions.
Authors
- Prathap Simhadri (ORCID: https://orcid.org/0000-0002-3209-8466)
- Nihar Jena (ORCID: https://orcid.org/0000-0002-7702-9034)
- Deepak Chandramohan (ORCID: https://orcid.org/0000-0001-9455-9822)
- Prabhat Singh (ORCID: https://orcid.org/0009-0007-5264-2557)
- Michael R. Filoramo
- Renish Contractor
Institutions
- University of Alabama (US)
- Wayne State University (US)
- Daytona State College (US)
- CHRISTUS Spohn Hospital Corpus Christi - Memorial (US)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/ccr3.9308
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00